Ipsen Reports Solid Sales Growth in First Quarter 2020 With Limited COVID-19 Impact
IPSEN SA S/ADR (IPSEY)
NASDAQ:AMEX Investor Relations:
ipsen.com/investors
Company Research
Source: Business Wire
Continued momentum with Q1 2020 Group sales growth of 9.6% as reported, or 8.7%1 at constant exchange ratesLimited Q1 2020 financial impact from COVID-19 given resilient Specialty Care product portfolio comprised mostly of highly-differentiated treatments for critical conditions. Levels of inventory are adequate and no supply chain issues are anticipated. Limited disruption to ongoing clinical trials 2020 Guidance remains suspended as announced in March given the uncertainty around the duration and scale of the COVID-19 pandemicSignificant progress for palovarotene with clearance to re-initiate dosing in fibrodysplasia ossificans progressiva (FOP) patients 14 years of age and older, and complete response submitted to the FDA’s questions related to the partial clinical hold on patients under 14 years of age in palovarotene trialsFocus on near-term priorities: executing on COVID-19 business continuity plan, identifying a new CEO and determining the regulatory pathway for palovarotene fo
Show less
Read more
Impact Snapshot
Event Time:
IPSEY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IPSEY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IPSEY alerts
High impacting IPSEN SA S/ADR news events
Weekly update
A roundup of the hottest topics
IPSEY
News
- Ipsen appoints Keira Driansky as EVP, President of North AmericaGlobeNewswire
- Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidanceGlobeNewswire
- Ipsen en Skyhawk Therapeutics kondigen samenwerking aan op het gebied van onderzoek naar RNA-targeting bij zeldzame neurologische aandoeningenPR Newswire
- Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseasesPR Newswire
- Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseasesPR Newswire